Abstracts of up to 300 words should be submitted electronically using the form on this page before midnight on 15th December 2017.
Please note that abstracts submitted in the wrong format will be rejected.
The senior author must be prepared to endorse the abstract. If the senior author is not a member of BSCOS then the submission must be sponsored by a member of the society, and their endorsement indicated. In the event of authors not being able to obtain endorsement they should contact the Hon Sec.
i. The title: entire title in capital letters, without abbreviations.
ii. Author’s initial/s and first letter of surname in capital letters; remainder of name in lower case (eg. J.F. Bloggs).
iii. The institution where work was carried out.
iv. A statement of the purposes of the study (one sentence).
v. A summary of the methods used and the results.
vi. A statement of the conclusion. (It is not acceptable to state “The results will be discussed”).
vii. The word count (sections iv, v & vi) must be stated and must not exceed 300 words
viii. The level of evidence (as per JBJS guidelines) must be stated
Tables, pictures, graphs and other images should not be included.
Only common abbreviations should be used. If unusual abbreviations are used, the full phrase must be used in parentheses the first time it appears.
Do not mention sponsors.
Do not use commercial names of medicines.
FONT SHOULD BE TIMES NEW ROMAN, PT 11.
SINGLE LINE SPACING SHOULD BE USED.
DO NOT EMBOLDEN OR UNDERLINE ANY TEXT.
IF ORGANISATION OF CONTENT IS NOT FOLLOWED THE ABSTRACT WILL BE REJECTED
Once your abstract is received an automatic acknowledgement will be sent to your email address. The decision of the Executive Committee will be delivered electronically between 25th and 31st December 2017.